Essec\Faculty\Model\Contribution {#2233
#_index: "academ_contributions"
#_id: "14056"
#_source: array:26 [
"id" => "14056"
"slug" => "use-of-ibrutinib-in-real-life-settings-in-france-results-from-a-retrospective-observational-study-using-the-snds-database-osiris"
"yearMonth" => "2022-11"
"year" => "2022"
"title" => "Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS)"
"description" => "CHOQUET, S., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G., MARCHAL, C., BELHASSEN, M. ... LEVY, V. (2022). Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS). Dans: American Society of Hematology Conference."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CHOQUET Sylvain"
]
2 => array:1 [
"name" => "DESLANDES Marine"
]
3 => array:1 [
"name" => "MACHER Nahid"
]
4 => array:1 [
"name" => "MARCHAL Clarisse"
]
5 => array:1 [
"name" => "BELHASSEN Manon"
]
6 => array:1 [
"name" => "JACOUD Flore"
]
7 => array:1 [
"name" => "LEVY Vincent"
]
]
"ouvrage" => "American Society of Hematology Conference"
"keywords" => []
"updatedAt" => "2023-06-26 10:59:48"
"publicationUrl" => "https://doi.org/10.1182/blood-2022-162213"
"publicationInfo" => array:3 [
"pages" => "9898-9899"
"volume" => "140"
"number" => "Supplement 1"
]
"type" => array:2 [
"fr" => "Communications dans une conférence"
"en" => "Presentations at an Academic or Professional conference"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Ibrutinib is a Bruton's Tyrosine Kinase Inhibitor indicated in the treatment of several B-cell malignancies: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström Macroglobulinemia (WM). The number and the characteristics of patients treated by Ibrutinib in France in real life settings are unknown and need to be determined, as well as treatment pattern in real-life settings."
"en" => "Ibrutinib is a Bruton's Tyrosine Kinase Inhibitor indicated in the treatment of several B-cell malignancies: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström Macroglobulinemia (WM). The number and the characteristics of patients treated by Ibrutinib in France in real life settings are unknown and need to be determined, as well as treatment pattern in real-life settings."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-12-22T16:21:42.000Z"
"docTitle" => "Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS)"
"docSurtitle" => "Communications dans une conférence"
"authorNames" => "<a href="/cv/de-pouvourville-gerard">PUYOU DE POUVOURVILLE Gérard</a>, CHOQUET Sylvain, DESLANDES Marine, MACHER Nahid, MARCHAL Clarisse, BELHASSEN Manon, JACOUD Flore, LEVY Vincent"
"docDescription" => "<span class="document-property-authors">PUYOU DE POUVOURVILLE Gérard, CHOQUET Sylvain, DESLANDES Marine, MACHER Nahid, MARCHAL Clarisse, BELHASSEN Manon, JACOUD Flore, LEVY Vincent</span><br><span class="document-property-authors_fields">Management</span> | <span class="document-property-year">2022</span>"
"keywordList" => ""
"docPreview" => "<b>Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS)</b><br><span>2022-11 | Communications dans une conférence </span>"
"docType" => "research"
"publicationLink" => "<a href="https://doi.org/10.1182/blood-2022-162213" target="_blank">Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS)</a>"
]
+lang: "fr"
+"_type": "_doc"
+"_score": 8.764241
+"parent": null
}